95 related articles for article (PubMed ID: 4037525)
1. Pharmacokinetic studies on antituberculosis regimens in humans. I. Absorption and metabolism of the compounds used in the initial intensive phase of the short-course regimens: single administration study.
Acocella G; Conti R; Luisetti M; Pozzi E; Grassi C
Am Rev Respir Dis; 1985 Sep; 132(3):510-5. PubMed ID: 4037525
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
6. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
[TBL] [Abstract][Full Text] [Related]
8. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
Smith PJ; van Dyk J; Fredericks A
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma.
Zhou Z; Wu X; Wei Q; Liu Y; Liu P; Ma A; Zou F
Anal Bioanal Chem; 2013 Jul; 405(19):6323-35. PubMed ID: 23719934
[TBL] [Abstract][Full Text] [Related]
10. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
12. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
13. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis.
Kaojarern S; Supmonchai K; Phuapradit P; Mokkhavesa C; Krittiyanunt S
Clin Pharmacol Ther; 1991 Jan; 49(1):6-12. PubMed ID: 1988241
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
[TBL] [Abstract][Full Text] [Related]
15. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
[TBL] [Abstract][Full Text] [Related]
16. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
[TBL] [Abstract][Full Text] [Related]
17. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
18. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
Panchagnula R; Kaur KJ; Singh I; Kaul CL
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
[TBL] [Abstract][Full Text] [Related]
19. LC-QToF-MS method for quantification of ethambutol, isoniazid, pyrazinamide and rifampicin in human plasma and its application.
Fachi MM; Vilhena RO; Boger B; Domingos EL; Dos Santos JMMF; Junkert AM; de Fátima Cobre A; Momade DRO; Beraldi-Magalhães F; de Liz MV; Cordeiro-Santos M; Pontarolo R
Biomed Chromatogr; 2020 May; 34(5):e4812. PubMed ID: 32068899
[TBL] [Abstract][Full Text] [Related]
20. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study.
Am Rev Respir Dis; 1981 Feb; 123(2):165-70. PubMed ID: 7015933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
